Anti-SARS-CoV-2 antibody response after 2 and 3 doses of BNT162b2 mRNA vaccine in patients with lymphoid malignancies.
COVID-19
Haematologicalmalignancies
Immunocompromised
Third dose
Vaccine
Journal
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
27
11
2021
revised:
10
02
2022
accepted:
19
02
2022
pubmed:
9
3
2022
medline:
27
5
2022
entrez:
8
3
2022
Statut:
ppublish
Résumé
COVID-19 patients affected by haematological malignancies have a more severe course of the disease and higher mortality, prompting for effective prophylaxis. The present study aims to evaluate the humoral response after mRNA vaccination as well as the impact of a third vaccine dose in patients with lymphoid malignancies. We conducted a single-centre study, evaluating the serological responses of mRNA vaccination amongst a cohort of 200 patients affected by lymphoid malignancies after two or three doses using an industrial SARS-CoV-2 serology assay for anti-receptor binding domain (RBD) Spike IgG detection and quantification. Among patients with plasma cell disorders, 59 of 96 (61%) had seroconversion (anti-RBD >50 AU/mL), and recent anti-CD38 therapies were associated with lower serological anti-RBD IgG concentrations (median IgG concentration 137 (IQR 0-512) AU/mL vs. 543 (IQR 35-3496) AU/mL; p < 0.001). Patients with B-cell malignancies had a lower seroconversion rate (20/84, 24%) mainly due to the broad usage of anti-CD20 monoclonal antibodies; only 2 of 53 (4%) patients treated by anti-CD20 antibodies during the last 12 months experienced a seroconversion. A total of 78 patients (44 with plasma cell disorders, 27 with B-cell malignancies, and 7 with other lymphomas) received a third dose of vaccine. The seroconversion rate and antibody concentrations increased significantly, especially in patients with plasma cell disorders, where an increment of anti-RBD IgG concentrations was observed in 31 of 44 (70%) patients, with an anti-RBD concentration median-fold increase of 10.6 (IQR 2.4-25.5). Its benefit in B-cell malignancies is uncertain, with only 2 of 25 (8%) patients having seroconverted after the vaccine booster, without increased median antibody concentration. A third mRNA vaccine dose significantly improved humoral responses among patients with plasma cell disorders, whereas the effect was limited among patients with B-cell malignancies.
Identifiants
pubmed: 35259530
pii: S1198-743X(22)00106-9
doi: 10.1016/j.cmi.2022.02.029
pmc: PMC8897197
pii:
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
Immunoglobulin G
0
RNA, Messenger
0
Vaccines, Synthetic
0
mRNA Vaccines
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
885.e7-885.e11Informations de copyright
Copyright © 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Références
Nat Med. 2021 Jul;27(7):1280-1289
pubmed: 34017137
N Engl J Med. 2021 Aug 12;385(7):661-662
pubmed: 34161700
Nat Med. 2021 Jun;27(6):981-984
pubmed: 33795870
J Hematol Oncol. 2021 May 17;14(1):81
pubmed: 34001183
Lancet Rheumatol. 2022 Jan;4(1):e13-e16
pubmed: 34778844
Ann Rheum Dis. 2021 Oct;80(10):1345-1350
pubmed: 34285048
Cancers (Basel). 2021 Jul 28;13(15):
pubmed: 34359701
Lancet Rheumatol. 2021 Nov;3(11):e789-e797
pubmed: 34514436
Blood Cancer J. 2021 Sep 14;11(9):151
pubmed: 34521813
Cancer Cell. 2021 Oct 11;39(10):1297-1299
pubmed: 34509182
ESMO Open. 2021 Oct;6(5):100274
pubmed: 34597941
Am J Hematol. 2021 Aug 1;96(8):934-944
pubmed: 33909916
Cancer Cell. 2021 Aug 9;39(8):1028-1030
pubmed: 34242572